<DOC>
	<DOCNO>NCT03082183</DOCNO>
	<brief_summary>The primary objective trial investigate relative bioavailability single dose BI 425809 give alone ( Reference , B ) compare co-administration ( Test , A ) 7th day 10-day treatment rifampicin follow oral administration healthy male volunteer .</brief_summary>
	<brief_title>DDI Strong CYP3A4 Inducer</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy male subject accord assessment investigator , base complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age 18 55 year ( incl . ) BMI 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 50 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Use drug within 30 day prior administration trial medication might reasonably influence result trial ( incl . QT/QTc interval prolongation ) Participation another trial investigational drug administer within 60 day prior plan administration trial medication , current participation another trial involve administration investigational drug Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke specify trial day Alcohol abuse ( consumption 20 g per day ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study In addition , follow trialspecific exclusion criterion apply : History relevant liver disease disturbance liver function , jaundice , drug induce liver injury , DubinJohnson syndrome , Rotor syndrome , liver tumour Thrombocytes low limit normal liver enzyme ( ALT , AST , GGT , AP ) upper limit normal screening examination</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>